What's Your APR?

My Recent Stock Picks: Gains and Annualized Returns

My Recent Stock Picks: Gains and Annualized Returns That Pack a Punch!

As an investor always on the lookout for promising opportunities, I recently dove into a diverse set of stocks and ETFs, from tech innovators to precious metals. With the help of Grok 3, an AI-powered tool from xAI, I’ve crunched the numbers to see how my portfolio is performing and annualized the returns to get a sense of their potential. The results? Some impressive gains in a short time! Let’s break down my holdings, their unrealized gains, and the effective Annual Percentage Rates (APRs) that show what these returns could mean if sustained over a year.

The Portfolio Snapshot

Using current market prices as of September 15, 2025, and my unrealized gains, Grok 3 estimated how long I’ve likely held each position (based on recent price data) and calculated the effective APR. Here’s the rundown:

Ticker Full Name Unrealized Gain (%) Holding Period (Days) Effective APR (%)
CRDO Credo Technology Group Holding Ltd +49.84 87 305.77
SLV iShares Silver Trust +16.36 67 109.28
SES SES AI Corporation +12.32 41 150.80
FUBO fuboTV Inc. +11.48 45 113.75
MBRX Moleculin Biotech, Inc. +5.42 12 254.26
SOUN SoundHound AI, Inc. +5.12 12 233.91
OPEN Opendoor Technologies Inc. +4.14 10 223.13
VNQ Vanguard Real Estate ETF +2.18 6 183.76

Standout Performers

Credo Technology (CRDO) takes the crown with a jaw-dropping 49.84% gain in just 87 days, translating to an annualized return of 305.77%. This tech stock’s surge reflects its strong position in high-speed connectivity solutions—a hot sector in today’s digital economy.

iShares Silver Trust (SLV) delivered a solid 16.36% gain in 67 days, annualizing to 109.28%. With silver often seen as a hedge against inflation, this ETF’s performance suggests a timely bet on precious metals.

Moleculin Biotech (MBRX) and SoundHound AI (SOUN), both held for just 12 days, posted gains of 5.42% and 5.12%, respectively, with APRs of 254.26% and 233.91%. These short-term wins highlight the potential of biotech and AI-driven companies, though their volatility calls for careful monitoring.

Even the Vanguard Real Estate ETF (VNQ), with a modest 2.18% gain in 6 days, annualizes to an impressive 183.76%, showing real estate’s steady appeal in a short window.

Why These Numbers Matter

The effective APRs give a sense of what these gains could look like if sustained over a year, though short holding periods can inflate these figures. For instance, MBRX’s 254.26% APR over 12 days doesn’t mean I expect that return annually—it’s a snapshot of momentum. Using Grok 3 to calculate these metrics helps me stay on top of my portfolio’s performance and spot trends early.

What’s Next?

These early gains are exciting, but investing is a long game. I’ll keep tracking these positions, balancing high-fliers like CRDO with steadier bets like VNQ. Grok 3’s ability to analyze price data and estimate holding periods has been a game-changer, giving me clarity without hours of manual number-crunching.

What’s your latest investment win? Drop a comment below, and let’s talk markets! For those curious about diving deeper into portfolio analysis, check out Grok 3 at x.ai/grok to see how it can power your financial insights.

Comments

Post a Comment

Popular posts from this blog

WULF Moderate Risk High Potential For Return

TeraWulf Inc. (WULF): A Swing Trading Opportunity with 30% Chance of 60% Return Date: July 29, 2025 | Stock Price: $5.19 | Market: NASDAQ Grok assisted blog accuracy not guaranteed  Research suggests TeraWulf Inc. (WULF) offers a compelling swing trading opportunity, with a 30% chance of achieving a 60% return , potentially reaching $8.30 from its current price of $5.19. This potential is driven by upcoming earnings, Bitcoin market trends, and the company’s strategic pivot to high-performance computing (HPC) hosting. Here’s a detailed breakdown for swing traders looking to capitalize on this high-risk, high-reward stock. Stock Overview TeraWulf Inc., a Technology Services company in the Data Processing Services sector, is a Bitcoin miner transitioning to HPC hosting for AI and cloud computing. Trading at $5.19 as of 10:35 AM CDT on July 29, 2025, WULF has a 52-week range of $2.06–$9.30, reflecting its vol...
Read more

ZKIN I'm Inn

Is ZKIN the Next Big Swing Trade Opportunity? Technical Analysis and Trade Plan (I generated this blog post from the Sleep Inn Oklahoma City Bricktown with the help of Grok accuracy is not guaranteed) ZK International Group Co., Ltd. (NASDAQ: ZKIN) is catching the eye of swing traders with its recent price action, high volatility, and potential catalysts. Priced at $1.88 (as of August 19, 2025), ZKIN offers a compelling setup for traders looking to capitalize on short-term price swings. This blog post dives into the technical and fundamental factors driving this opportunity, outlines two trade setups, and provides a step-by-step guide to execute them. Click the dropdowns for deeper insights! Why ZKIN? The Opportunity at a Glance ZKIN, a small-cap stock with a $9.71M market cap, operates in the steel and cryptocurrency sectors, with recent developments like a Shenzhen Gas Group contract and the upcoming xSigma Wallet launch fueling optimism. ...
Read more

INHD Inhibikase Therapeutics

INHD Swing Trade Setup: High-Reward Opportunity for Aggressive Traders Posted on August 29, 2025 Grock assisted log accuracy not guaranteed Hey traders! If you’re looking for a high-octane swing trade with big potential, Inhibikase Therapeutics (INHD) might be your next play. Inspired by momentum-driven traders like @TigerLineTrades and recent buzz on X (like @timothysykes calling out INHD’s spike from $2.60s to $3.80s), I’ve put together an aggressive swing trade setup targeting 30–90% returns in just 1–3 days. Here’s the breakdown, complete with entry points, exit targets, and key indicators to watch. Let’s dive in! Why INHD? The Setup Explained INHD, a clinical-stage biotech, is making waves with its work on Parkinson’s and pulmonary arterial hypertension (PAH). Recent catalysts, like FDA approval for a late-stage PAH trial and $275M in financing (August 2025), have fueled volatility—perfect for swing traders chasing quick gains. With a recent ...
Read more